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Background: Deficiency in tuberin results in activation the mTOR pathway and leads to accumulation of cell matrix
proteins. The mechanisms by which tuberin regulates fibrosis in kidney angiomyolipomas (AMLs) of tuberous
sclerosis patients are not fully known.
Method: In the present study, we investigated the potential role of tuberin/mTOR pathway in the regulation of cell
fibrosis in AML cells and kidney tumor tissue from tuberous sclerosis complex (TSC) patients.
Results: AML cells treated with rapamycin shows a significant decrease in mRNA and protein expression as well as
in promoter transcriptional activity of alpha-smooth muscle actin (α-SMA) compared to untreated cells. In addition,
cells treated with rapamycin significantly decreased the protein expression of the transcription factor YY1.
Rapamycin treatment also results in the redistribution of YY1 from the nucleus to cytoplasm in AML cells. Moreover,
cells treated with rapamycin resulted in a significant reduce of binding of YY1 to the αSMA promoter element in
nuclear extracts of AML cells. Kidney angiomyolipoma tissues from TSC patients showed lower levels of tuberin and
higher levels of phospho-p70S6K that resulted in higher levels of mRNA and protein of αSMA expression compared
to control kidney tissues. In addition, most of the α-SMA staining was identified in the smooth muscle cells of AML
tissues. YY1 was also significantly increased in tumor tissue of AMLs compared to control kidney tissue suggesting
that YY1 plays a major role in the regulation of αSMA.
Conclusions: These data comprise the first report to provide one mechanism whereby rapamycin might inhibit the
cell fibrosis in kidney tumor of TSC patients.
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Tuberous Sclerosis complex (TSC) is a genetic disorder
that causes tumors to form in many organs. Loss of
heterozygosity (LOH) at the TSC1 or TSC2 loci has been
detected in TSC-associated hamartomas and renal cell
carcinoma (RCC) as well as in sporadic tumors of non-
TSC patients [1,2]. Kidney cancer development is rare
in TSC, occurring in only 2–3% of all patients [3-5].
Multicentric angiomyolipomas are much more common
in patients with TSC than RCCs, but may, nonetheless,
have similar underlying genetic basis at early steps in their
genesis and/or progression, specifically in the setting of* Correspondence: habib@uthscsa.edu
1Geriatric Research, Education and Clinical Department, South Texas Veterans
Health Care System, San Antonio, TX, USA
3Department of Cellular and Structural Biology, University of Texas Health
Science Center at San Antonio, San Antonio, TX, USA
Full list of author information is available at the end of the article
© 2013 Liang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortuberin deficiency [6]. Angiomyolipomas (AMLs) are
benign kidney tumors composed of smooth muscle,
fat, and vessel cells. Renal angiomyolipomas tend to be
larger, bilateral, multifocal and present at a younger
age compared with sporadic forms [7]. Angiomyolipomas
most commonly occur in the kidneys and, although
often asymptomatic, may enlarge and bleed leading to
hemorrhage and renal impairment [8-10]. The lesions
are usually benign although rare malignant cases have
been described, often consisting of only the smooth
muscle component [10].
The TSC2 gene product, tuberin, is a tumor suppressor
protein whose absence or inactivation is associated
with several defects such as abnormal cellular migration,
proliferation, and differentiation [11-13]. Tuberin expres-
sion was initially induced following acute renal injury,
suggesting that the TSC2 may function as an acute-phasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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injury [14]. The smooth muscle cell component of
angiomyolipoma is thought to derive from a precursor
termed the perivascular epithelioid cell (PEC) [15]. PEC-
derived lesions, which include lymphangioleiomyomatosis
(LAM), a cystic lung disease, are characterized by the
dual expression of smooth muscle and melanocytic
features [16]. Angiomyolipoma is rare in the general
population but is present in 80% of patients with TSC,
an autosomal dominant tumor suppressor syndrome
characterized by multiple hamartomas in the central
nervous system, skin and other organs [17]. Although
TSC occurs equally in men and women, angiomyolipoma
is more common and larger in women and is thought
to be estrogen dependent. In vitro, the growth of cells
derived from angiomyolipoma can be enhanced by
estrogen [18]. Thus, it is likely that although LAM
and angiomyolipoma result from the loss of tuberin
or hamartin. Unlike other TSC related hamartomas,
their growth is promoted by estrogen.
The mammalian target of rapamycin (mTOR) serves a
critical role in regulating the translational machinery
that affects growth, proliferation, and differentiation, all
of which are abnormally manifested in TSC lesions
[19,20]. These lesions are associated with accumulation
of fibrotic proteins but the mechanisms by which
tuberin regulates these proteins has not been explored.
In the current study, we examined the role of tuberin/
mTOR in regulating α-SMA in TSC patients. Here, we
report for the first time that tuberin/mTOR pathways
regulate α-SMA through redistribution the transcription
factor YY1 from the cytoplasm to the nucleus in AML
cells. In addition, binding of YY1 to α-SMA promoter
may provide a mechanism for enhancing the expression
α-SMA to increase cell fibrosis in kidney angiomyolipoma
of TSC patients.
Results
Inhibition of mTOR decreases protein and mRNA
expression of αSMA
To determine the effect of mTOR inhibition on αSMA,
AML cells were treated with different concentrations of
rapamycin (0-40 nM) for 24 h. Protein and RNA from
untreated and rapamycin treated cells were extracted
and subjected to Western blot and RT-PCR analysis.
Cells treated with rapamycin (40 nM) showed significant de-
crease in mRNA of αSMA products compared to untreated
cells or cells treated with low concentrations of rapamycin
(20nM) (Figure 1A). In addition, significant decreased
in αSMA protein expression showed in cells treated
with same concentration of rapamycin (Figure 1B). These
data suggests that inhibition of mTOR by rapamycin is
sufficient to downregulate the αSMA at transcription and
translation levels.Rapamycin significantly decreased YY1 protein expression
and αSMA promoter activity
To determine whether decreases in mRNA and protein
expression were reflected in changes in αSMA promoter
activity through YY1, AML cells were transfected with
αSMA promoter luciferase construct. Cells treated with
different concentrations of rapamycin (0-40 nM) for 24 h
showed a significant decrease in YY1 protein expression
by Western blot analysis (Figure 1C). YY1 is a potential
transcription factor that regulates αSMA. In the next ex-
periment we have tested the effect of rapamycin treatment
on regulation of the promoter activity of αSMA in AML
cells. A reporter plasmid containing the αSMA promoter
driving expression of the luciferase and a control Renilla
reporter gene were co-transfected into AML cells. Cells
were treated with different concentrations of rapamycin
(0-40 nM) for 24 h then luciferase activity was deter-
mined using the Luciferase Reporter Assay System by a
luminometer and normalized by Renilla reporter activity.
Data in Figure 1D showed that rapamycin treatment
resulted in a significant decrease in αSMA promoter
activity compared to untreated cells suggesting the role
of mTOR in transcriptional regulation of αSMA.
Inhibition of mTOR results in redistribution of YY1 from
the nucleus to cytoplasm in AML cells
Immunofluorescene staining was used to detect the
localization of YY1 in AML cells treated with rapamycin
(0–40 nM) for 24 hours. Overlay staining of YY1 and DNA
staining, demonstrating nuclear localization of YY1 in non
treated AML cells while cytoplasmic staining of YY1 was
detected in treated cells with rapamycin (Figure 2A-C). We
have confirmed the redistribution of YY1 by Western blot
analysis in cytoplasmic and nuclear fractions of untreated
and treated AML cells with 40 nm rapamycin (Figure 2D).
These data suggested that treatment with rapamycin
increases the cytoplasmic redistribution of YY1 that
may results in decreased αSMA in nucleus. However,
redistribution of YY1 localization by rapamycin indicating
that activation of the mTOR pathway plays an important
role in the activation of fibrosis signaling in AML cells.
Tuberin regulates αSMA
To determine whether tuberin regulates αSMA expression
through TSC2, tuberin was downregulated using duplex
siRNA oligonucleotide complementary to TSC2 in human
embryonic kidney (HEK293) cells. Downregulation of
tuberin results in increased αSMA expression compared
with cells transfected with scrambled control oligonucleo-
tides (Figure 3A). In contrast, overexpression of tuberin in
HEK293 cells using an adenovirus expressing tuberin
(Ad-TSC2) results in decreased αSMA protein expression,
indicating that tuberin is an upstream regulator of αSMA
in AML cells. In addition, cells transfected with siRNA
A B 
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Figure 1 Rapamycin decreases of αSMA in AML cells. AML cells were treated with different concentrations of rapamycin (0-40 nM) for 24 h.
Western blot analysis was performed in cell lysates using αSMA antibody. (A) Cells treated with 40 nM of rapamycin showed significant decrease
in protein expression of αSMA. Inhibition of mTOR decreases mRNA of αSMA in AML cells. RNA from untreated and rapamycin treated AML cells
were extracted and subjected to RT-PCR analysis. (B) mRNA of αSMA products were separated on agarose gel electrophoresis and visualized by
ethidium bromide staining under UV light. (A) Cells treated with 40 nM of rapamycin showed also significant decrease in mRNA of αSMA. GAPDH
was used as a loading control. Significant difference from untreated cells is indicated by **P < 0.01 and *P < 0.05. Rapamycin significantly
decreased YY1 protein expression and αSMA promoter transcriptional activity in AML cells. AML cells were treated with different concentrations
of rapamycin (0-40 nM) for 24 h. (C) Protein from untreated and rapamycin treated AML cells were extracted and subjected to Western blot
analysis. Treated AML cells with rapamycin (0-40 nM) for 24 results in significant decreased in YY1 protein expression (D) A reporter plasmid
containing the αSMA promoter driving expression of the luciferase and a control Renilla reporter gene were co-transfected into the cells using
LipofectAMINE Plus ReagentTM. After treatment with different concentrations of rapamycin for 24 h. Luciferase activity was determined using the
Luciferase Reporter Assay System by a luminometer and normalized by Renilla reporter activity. Histograms represent means ± SE (n = 6).
Significant difference from cells treated with rapamycin is indicated by *P < 0.01.
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high glucose (HG, 25 mM) for 24 h showed a significant
increase in αSMA protein expression (Figure 3B). More-
over, cells infected with adenovirus expressing tuberin and
treated with HG confirmed that upregulation of tuberin
resulted in significant decrease in αSMA protein expression
under both low and high-energy conditions (Figure 3B).
Rapamycin treatment significantly reduces the binding of
YY1 to the αSMA promoter element
To further investigate the mechanism by which inhibition of
mTOR affect the binding of YY1 to DNA-binding site in
the αSMA promoter, EMSA was performed using nuclear
extracts of AML cells. Intact 28-bp double-strand end-
labeled oligonucleotides containing the sites spanning the
region −556 to −526 of the YY1 that binds to the αSMA
promoter was used as a DNA probe (Figure 4A). Labeled
probe was incubated with nuclear extracts isolated from
untreated or treated rapamycin AML cells. Treatment of
AML cells with 20-40 nM rapamycin significantly reduced
YY1 in the nuclear extracts compared to untreated cells
(Figure 4B). In addition, incubation of nuclear extracts withmutant of YY1 oligonucleotide in TTT to AAA base substi-
tutions showed no binding to YY1 promoter-specific DNA
complexes. To confirm the specificity of the protein-DNA
interaction, the cell extracts were also pre-incubated with an
antibody recognizing YY1 (Active Motif, Carlsbad, CA) or
with a nonspecific antibody. The DNA-protein complexes
were significantly abolished in the presence of the YY1
antibody, but not by IgG, indicating that YY1 is indeed a
component of these complexes (Figure 4C). These data
suggest that inhibition of mTOR results in regulation
the binding of YY1 to αSMA promoter to block cell fibrosis
in AML cells.
Mutation of YY1 reduces αSMA promoter activity
αSMA plasmid constructs contained wild type (WT) and
mutant of YY1 driving expression of the luciferase were
transfected into AML cells. A control Renilla reporter gene
was co-transfected into AML cells. Luciferase activity was
determined using the Luciferase Reporter Assay System by
a luminometer and normalized by Renilla reporter activity.
Data in Figure 4D showed that mutation in YY1 signifi-




Figure 2 Rapamycin treatment results in the redistribution of YY1 from the nucleus to cytoplasm in AML cells. Immunofluorescene
staining was used to detect the localization of YY1 in AML cells treated with rapamycin (0–40 nM) for 24 hours. (A) FITC green signals for YY1
were detected using a filter with excitation range of 488 nm and (B) propidium iodide red signals for nuclear DNA using a filter with excitation
at 535 nm. (C) Overlay of YY1 and DNA staining, demonstrating nuclear localization of YY1 in AML cells treated with rapamycin. To show staining
specificity, control cells were stained without primary antibody. (D) Rapamycin treatment significantly decreased YY1 in the nuclear fraction.
Lamin B was used as a nuclear marker and GAPDH as cytoplasmic marker.
A B
Figure 3 Tuberin regulates αSMA expression in human cells. (A) Immunoblot analysis shows that downregulation of tuberin with siRNA
directed against TSC2 results in an increased in αSMA protein expression in human renal embryonic epithelial cells (HEK293) in cells grown in
normal glucose or pretreated with high glucose (25 mM) for 24 h. (B) Overexpression of tuberin decreases αSMA expression. HEK293 cells were
infected with adenovirus 6.01 expressing tuberin complementary DNA. An adenovirus vector expressing protein (Ad-GAL) was used as a control.
Overexpression of tuberin results in decreased αSMA protein expression in cells grown in normal glucose or pretreated with high glucose
(25 mM) for 24 h. GAPDH was used as a loading control.




Figure 4 Rapamycin treatment significantly reduces the binding of YY1 to the αSMA promoter element. (A) EMSA analysis of a DNA
probe corresponding to the putative YY1 binding site in the αSMA promoter. Labeled probes were incubated with nuclear extracts isolated from
untreated and treated AML cells with different concentrations of rapamycin (0–40 nM). (B) Treatment of AML cells with 20-40 nM of rapamycin
significantly reduced YY1 in the nuclear extracts compared to untreated cells and cells. Mutant of YY1 oligonucleotide in TTT to AAA base
substitutions showed no binding to YY1 promoter-specific DNA complexes (Lane 5 was moved from its original position on the gel).
(C) The specificity of binding of the DNA/protein complex to YY1 was demonstrated by adding YY1 antibody to the reaction mixture. Including
the YY1 antibody in the reaction results in markedly reduced the specific DNA/protein complex. (D) A reporter plasmid of αSMA promoter driving
expression of the luciferase contained wild type or mutant of YY1 was transfected into AML cells. Control Renilla reporter gene was co-transfected into
the cells using LipofectAMINE Plus ReagentTM. Luciferase activity was determined using the Luciferase Reporter Assay System by a luminometer and
normalized by Renilla reporter activity. Histograms represent means ± SE (n = 6). Significant difference from cells transfected with wild type YY1 is
indicated by *P < 0.01.
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of αSMA.
Deficiency in tuberin and activation of mTOR result in
increased YY1 in tumor kidney tissue of TSC patients
Tuberin and phosho-p70S6K as well as total p70S6K
protein expression were measured in normal kidney (C)and tumor kidney (T) from patients with tuberous
sclerosis by Western blot analysis. Data in Figure 5A &
B showed significant decreased in tuberin expression
was associated with increased in mTOR activity that
measured by phosphorylation of p70S6K at Thr389
confirming that deficiency in of tuberin activates
mTOR in kidney of TSC patients. Deficiency in tuberin
AB C
Figure 5 Deficiency of tuberin and activation of mTOR result in increased YY1 protein expression in tumor kidney tissue of TSC
patients. (A) Representative Immunoblot analysis showed significant decreased in tuberin and increased in phospho-p70S6K as well as YY1
protein expression in tumor kidney (T) from patients with tuberous sclerosis compared to normal kidney tissues. Actin was used as loading
control. (B & C’) Histograms represent means ± SE (n = 6). Significant difference from control is indicated by **P < 0.01.
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protein expression of YY1 in tumor kidney tissue of
patients with TSC (Figure 5A & C).
Upregulation of YY1 significantly increased in αSMA in
tumor kidney tissues of TSC patient
Protein and mRNA expression of αSMA in normal and
tumor kidney tissues from patients with tuberous sclerosis
were analyzed by Western blot and RT-PCR, respectively.
Data in Figure 6A & C showed a significantly increase in
mRNA of αSMA in tumor kidney tissue compared to nor-
mal tissues. In addition, protein expression of αSMA was
significantly increased in tumor kidney tissue compared to
normal tissues (Figure 6B & D). These data indicate that
deficiency in tuberin resulted in upregulation αSMA
protein expression and increase cell fibrosis through
increased YY1 expression in kidney angiomyolipomas
of TSC patients. Data in Figure 6E (a & b) showed H&E
staining of (a) normal tubular and glomerular structure in
control kidney tissue and (b) fat, vessel and smooth muscle
cells types in kidney angiomyolipoma tissue of TSC
patients. Kidney sections from normal and tumor of TSC
patients were stained with αSMA followed by horseradish
peroxidase staining. Data in Figure 6F (c & d) showed a few
cells stained with αSMA in normal kidney tissue while
(d) most of blood vessel and smooth muscle cells were
stained with αSMA in kidney tumor tissue.Discussion
This study provides the first evidence that tuberin regulates
the expression and promoter activity of the cell fibrosis
protein αSMA and that tuberin exerts this effect at least
partially through the transcription factor, YY1. The data
demonstrate that tuberin deficiency in AML cells is
associated with upregulation of αSMA protein and mRNA,
as well as with marked increase of αSMA promoter activity.
Downregulation of tuberin in HEK293 renal cells is associ-
ated with increased protein expression of αSMA. These
data indicate a novel role for tuberin in the regulation of
cell fibrosis protein and provide a potential mechanism by
which TSC2 mutations and tuberin deficiency predispose
to the genesis and progression of fibrosis in kidney
angiomyolipomas of TSC patients. Several approaches were
utilized to conclusively demonstrate that tuberin/mTOR
regulates αSMA. First, inhibition of mTOR by rapamycin
was associated with decrease in αSMA mRNA and protein
in AML cells. Second, inhibition of mTOR by rapamycin
inhibits the promoter activity of αSMA in AML through
decreased the protein expression of YY1. Third, rapamycin
treatment resulted in redistribution of YY1 from the
nucleus to cytoplasm in AML cells. Fourth, downregulation
of tuberin in renal epithelial cells by siRNA against
TSC2 was associated with increase in αSMA protein.
Upregulation of tuberin by introduction of TSC2 cDNA





Figure 6 Upregulation of YY1 results in significant increased in mRNA and protein expression of αSMA in tumor kidney tissues of TSC
patients. Representative RTPCR of mRNA (A) and immunoblot protein expression (B) of αSMA in normal kidney and tumor kidney tissues from
patients with tuberous sclerosis. Actin was used as loading control. (C’ & D) Histograms represent means ± SE (n = 6). Significant difference from
control is indicated by **P < 0.01. (E) H&E staining shows (a) a normal tubular and glomerular structure in control kidney tissue and (b) *fat, ^vessel
and # smooth muscle cells types in kidney angiomyolipoma tissue of TSC patients. (F) Kidney sections were stained with αSMA followed by
horseradish peroxidase staining. (c) Control of kidney shows a few cells stained with αSMA while (d) most of blood vessel and smooth muscle cells
were stained in kidney tumor tissue. Control sections in both procedures were incubated without primary antibody.
Liang et al. Molecular Cancer 2013, 12:49 Page 7 of 11
http://www.molecular-cancer.com/content/12/1/49in significant decreased in αSMA protein expression. In
addition, Inhibition of mTOR results in regulation the
binding of YY1 to αSMA promoter to block fibrosis inAML cells. Mutation in YY1 blocked the binding of YY1
to αSMA promoter and resulted in significant decrease
of αSMA promoter activity. Moreover, higher levels of
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angiomyolipoma tissue compared to control kidney tis-
sues. Furthermore, tumor tissue showed higher protein
expression of YY1 compared to control kidney tissue
suggesting that YY1 plays a major role in the regulation of
fibrosis in kidney angiomyolipoma tissue.
In general, fibrosis results from activation and differenti-
ation of fibroblasts, which overexpress extracellular matrix
proteins including αSMA. The decrease in αSMA mRNA
in AML cells suggests that decreased transcription is
one potential mechanism responsible for downregulation of
αSMA protein. YY1 has recently been shown to regulate
the transcription of αSMA in lung fibroblast cells [21]. YY1
binds to the αSMA promoter and activates αSMA tran-
scription. The YY1 binds to αSMA promoter in the region
between −556 and −526, which are important for binding
of YY1 to the consensus sequence of αSMA promoter.
Indeed, using EMSA, we found that YY1 binding was sig-
nificantly decreased in AML cells treated with rapamycin.
The specificity of the DNA protein complex was confirmed
by demonstrating significant decrease in the binding of
protein to DNA in the presence of anti-YY1antibody. Such
antibodies did significantly block nuclear proteins from
binding to αSMA promoter sites (Figure 3C). In addition,
mutation in YY1 significantly decreased αSMA promoter
activity in AML cells. Transcriptional activity using a
heterologous αSMA-luciferase promoter in AML cells
was also decreased in cells treated with rapamycin, clearly
demonstrating that tuberin/mTOR regulates α-SMA
through induction of its transcription. Collectively, the data
indicate the major role of YY1 in the regulation of αSMA
and fibrosis of kidney angiomyolipomas of TSC patients.
Our data showed that deficiency in tuberin and activation
of mTOR resulted in upregulation of YY1 in tumor kidney
tissue of TSC patients. The increase in mRNA and protein
expression of αSMA was associated with increase of YY1
protein expression in tumor kidney tissues. In addition, the
immunostaining data confirmed that most of blood vessel
and smooth muscle cells were stained with αSMA in
kidney tumor tissue. These data suggest that deficiency
in tuberin resulted in upregulation αSMA and increased
cell fibrosis through increased YY1 protein expression
in kidney angiomyolipomas of TSC patients. Because YY1
can directly bind to the promoter regions of α-SMA gene
[21] and is required for its expression, we suggest that
YY1 directly regulates a-SMA that is involved in fibroblast
activation and myofibroblast differentiation in kidney
angiomyolipomas. Thus, decreasing YY1 expression may
attenuate fibrotic responses by multiple mechanisms, in
keeping with a growing role for YY1 in cell survival in
response to injury [22,23]. In addition to direct effects
in fibroblasts, decreasing YY1 expression by rapamycin
may inhibit early inflammation during injury and repair
responses, and may help to protect against kidney fibrosisby this mechanism. In support of this idea, we showed
that inhibition of mTOR by rapamycin decreased YY1 pro-
tein expression and significantly decreased the promoter
activity of αSMA in AML cells. YY1 is generally considered
a constitutively expressed nuclear phosphoprotein, but
there is growing evidence that YY1 expression can be
dynamically regulated by chemotherapy. Our data in
Figure 2 showed the redistribution of YY1 from nucleus to
cytoplasm in AML cells treated with rapamycin supporting
this idea. In addition, case study showed that treatment of
TSC patients with low dose of rapamycin reduced the facial
angiofibromas, renal AML volume, improved of blood
pressure control and absent bleeding over 12 months
of treatment suggesting the role of rapamycin as an
anti-fibrotic and anti-proliferative drug [24].
Conclusions
In conclusions, deficiency in tuberin is associated with
increased expression of αSMA in AML cells as well as in
kidney tumor of patients with TSC. Treatment of AML
cells with mTOR inhibitor significantly decreased the accu-
mulation of αSMA, suggesting that tuberin plays a signifi-
cant role in protecting the cells from fibrosis. In addition,
deficiency of tuberin is sufficient to increase accumulation
of αSMA, with consequent increased the transcriptional
activity of αSMA through upregulation of YY1 (Figure 7).
The mechanisms by which tuberin deficiency regulates
kidney fibrosis in angiomyolipomas requires further study,
including investigating the potential of YY1 that directly
regulates several genes involved in fibrosis.
Materials and methods
Human tissue
Kidney angiomyolipoma tissue from TSC patients with
renal angiomyolipoma (total of 6) and unrelated healthy
people (total of 6) were obtained from the Brain and Tissue
Bank for Development Disorders (University of Maryland,
Baltimore, Maryland, USA). The study has been approved
by the Institutional Review Board of The University of
Texas Health Science Center at San Antonio, TX.
Cell culture
Angiomyolipoma cells derived from kidney human of
TSC patient were generously provided by Dr. Elizabeth
Henske (Harvard Medical School, MA). The cells were
grown in DMEM supplemented with 10% FBS. Human
embryonic kidney epithelial cells (HEK293) were obtained
from American Type Culture Collection (Manassas, VA)
and maintained in DMEM with 10% FBS. All cell lines were
grown at 37°C in a humidified atmosphere of 5% CO2.
Overexpression of tuberin
The human embryonic kidney (HEK293) cells were
grown to 30–50% confluence, made quiescent by serum
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Figure 7 Proposed model of regulation of fibrosis in kidney angiomyolipoma of tuberous sclerosis patients. Deficiency in tuberin and activation
of mTORC1 increased the accumulation of αSMA through upregulation of YY1 to fibrosis proteins in kidney angiomyolipoma of TSC patients.
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for 1 h with adenovirus 6.01 carrying the Tsc2 gene [25].
Viral stocks were prepared and tittered using the serial
dilution technique as described in the Adeno-X Expression
Systems User Manual (Clontech Laboratories). Infection
of cells with 20 multiplicity of infection (MOI) showed
appreciable expression of TSC2 protein. An adenovirus
vector expressing protein (Adβ-GAL) was used as a control.
The cells were then incubated for 48 h at 37°C in a hu-
midified atmosphere of 5% CO2. Cells were washed
twice with PBS buffer and western blot analysis was
performed on the cell extracts as above using tuberin
and αSMA antibodies.
siRNA experiments
HEK293 cells were grown in six-well plates. Prior to
transfection, cells (30–50% confluent) were washed with
PBS and media was replaced with 800 μl of OPTI-MEM
(Invitrogen, Carlsbad, CA). In parallel, 4 μl of oligofectamine
(Invitrogen, NY) were combined with 11 μl of OPTI-MEM
I and incubated at room temperature for 10 min. SMART
selected small interfering RNA (siRNA) duplexes of TSC2
with ‘UU’ overhangs and 5′ phosphate on the antisense
strand. The siRNA specific for TSC2 was a mixture of four
pooled duplexes. The TSC2 siRNA kit was obtained from
Dharmacon/Upstate, (Lake Placid, NY). According to
the manufacturer, these siRNA efficiently blocks tuberin
expression by 50–70%. The indicated duplex of 1.5 μg
were diluted into 180 μl of OPTI-MEM I, added to the
Oligofectamine/OPTI-MEM I mixture and incubated at
room temperature for 20 min. The siRNA complexes
were then added to the cells. After incubation for 3–4 h
in a 5% CO2 incubator, 1 ml of fresh medium was added
to a final serum concentration of 10%. Forty-eight hours
after transfection, cells were harvested for western blotanalysis. The control construct used in parallel experiments
contains four, pooled, non-specific siRNA duplexes
provided by with the kit [26].
Western analysis
Homogenates of kidney cortex or cell lysates were pre-
pared as described previously [27]. Protein concentrations
were determined with the Bradford assay using bovine
serum albumin as a standard [28]. Western blot analysis
was performed as described previously [29]. Tuberin,
phospho-p70S6K, and p70S6K antibodies were from Cell
Signaling (Boston, MA); GADPH and antibody was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA)
and Actin antibody from Calbiochem (Billerica, MA).
αSMA rabbit antibody was from Abcam (Cambridge, MA).
An enhanced chemiluminescence kit (Amersham, NJ) was
used to identify protein expression. Expression of each
protein was quantified by densitometry using National
Institutes of Health image 1.62 software and normalized
to a loading control.
Electrophoretic mobility shift assay
Nuclear proteins were extracted from AML cells as
described previously [26]. The protein concentration
of the nuclear extracts was determined using Bradford
method [28]. Electrophoretic mobility shift assay (EMSA)-
binding reactions were incubated in a 20 μl final volume for
20 min at room temperature containing 5 μg of the nuclear
extract, 20–30 fmol of the 5′ end-labeled double-stranded
21 bp oligonucleotide: 5’- AGTTCCTGGTTTCATTACTA
CAACACAA −3, covering the region of the αSMA pro-
moter from 556 to 526 (control), and 1 μl of poly (dI-dC).
Mutant oligonucleotide was designed as following: 5’-
AGTTCCTGGAAACATTACTACAACACAA −3. The
super shift assays were performed by pre-incubating
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Biotechnology) into the reaction. In addition, labeled
YY1 oligonucleotide at 556 to 526 (nt)- was incubated
with nuclear extracts of AML cells. The reaction was
carried out at room temperature for 30 min prior to
adding the radiolabelled probe. The complexes were
resolved using a 5% non-denaturing polyacrylamide gel.
The gels were dried and exposed overnight at −70°C.
Immunofluorescence staining of YY1
A double fluorescence labeling method was used as
described previously with minor modifications [27]. AML
cells in chamber slides were serum-starved for overnight
then treated with different concentrations of rapamycin
(0-40 nM) for 24 hours. The cells were washed with
PBS, fixed, and incubated with rabbit antibody against
YY1 (Cell Signaling Technology, MA), followed by sec-
ondary anti-rabbit IgG conjugated with FITC. The cells
were reacted with Vectashield Mounting Medium with
Propedium Iodide (PI) (Vector Laboratories). In this
assay, DNA was labeled with PI, and YY1 was identified
by the primary monoclonal antibody FITC green signals.
FITC green signals for YY1 were detected using a filter
with excitation range 450–490 nm and propidium iodide
red signals for nuclear DNA using a filter with excitation
at 535 nm. FITC and propidium iodide were detected
using an Olympus Research microscope equipped for
epifluorescence with excitation and band pass filters.
To show staining specificity, control cells were stained
without primary antibody.
Immunoperoxidase staining of αSMA
Detection of αSMA was performed on paraffin sections
of normal and tumor kidney by immunoperoxidase
histochemical staining [30]. Kidney sections underwent a
protease digestion step before they were incubated with
rabbit anti-αSMA antibody (Abcam, Cambridge, MA) for
30 min then washed twice with PBS. Sections were then
incubated with horseradish peroxidase labeled anti-rabbit
antibody for 30 min. The horseradish peroxidase was
developed with diaminobenzidine tetrahydrochloride
and hydrogen peroxide in PBS. Control sections in both
procedures were incubated without primary antibody.
Cell lysates fractionation
Cytoplasmic and nuclear protein fractions were extracted
from the cell lysates using a nuclear and cytoplasmic
fractionation kit (Pierce, Rockford, IL). The protein
concentration of the nuclear extracts was determined
using the Bradford method [28].
Quantitation of mRNA by RT-PCR
RNA was isolated from cells treated with rapamycin
(0-40 nM) using RNA Isolation Solvent (Tel-Test, Newark,NJ). In addition, RNA was extracted from kidney tissue
of control and tumors samples using RNeasy Mini
kit (Qiagen, Valencia, CA). RNA was quantitated by
spectrophotometery at 260 nm, and its integrity tested by
formaldehyde/agarose gel electrophoresis. RTPCR was
performed as previously described using the primers
(5’-3-ACGCTGGTCACCGTGGCGGC/5’- TTGCCGCTC
TTCTTGCCGCC) for αSMA. The amplified product
was 356-bp long. For GAPDH, an internal control of
amplification, upstream/reverse primers were 5'- GCCAC
CCAGAAGACTGTGGAT /5'- GAAGGCCATGCCAGT
GAGCT synthesizing a 528-bp product. The PCR products
were analyzed by electrophoresis on agarose gels and
ethidium bromide staining. The yield was determined
by densitometry and the ratio of αSMA to actin was
then calculated.
Transcriptional activity of αSMA promoter
A mouse αSMA promoter reporter plasmid was used to
determine the transcriptional activity of the αSMA gene.
αSMA plasmid constructs contained wild type or mu-
tant of YY1 were generously provided by Dr. Jia Guo
(University of Rochester Medical School, Rochester,
New York). A Renilla reporter plasmid (pRL-null) was
used as transfection control. Plasmids were transfected
into PPTE cells using the LipofectAMINE and Plus
Reagent method (Life Technologies, NY). LipofectAMINE
was added to the complex of DNA and Plus reagent and
incubated for 15 min at room temperature. DNA and Plus
reagent-LipofectAMINE complexes were added to each
well and incubated at 37°C with 5% CO2. After incubation
for 3–4 h, 1 ml of fresh media with 20% serum was added
to a final concentration of 10%. Cells were pre-treated
with rapamycin (0-40 nM) for 24 h. Forty-eight hours after
transfection, cells were harvested for Firefly and Renilla
luciferase assay using Dual-Luciferase Reporter assay kit
(Promega, Madison, WI). Luciferase activity was deter-
mined using the Luciferase Reporter Assay System and
a Turner luminometer according to the manufacturer's
instructions (Promega, Madison, WI) and normalized
to Renilla activity.
Statistics
Data are presented as mean ± standard error. Statistical
differences were determined using ANOVA followed by
Student Dunnett’s (Exp. vs. Control) test using 1 trial
analysis. P-values less than 0.05 and 0.01 were considered
statistically significant.
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